

THE PROBLEM
Uneven skintone is complex.
Hyperpigmentation, dark spots and discoloration are often persistent and influenced by multiple factors.
They don’t require aggressive solutions:
they require understanding.
THE SOLUTION
Consistency is the game changer.
There is no simple answer when it comes to hyperpigmentation or melasma.
From my clinical experience, most of the results are brought through a consistent skincare routine.
We developed this formula combining the latest researched actives in one product: complex on the inside, simple for your regimen.


THE INGREDIENTS


Helps improve the appearance of uneven skin tone and supports a more balanced-looking complexion. This nanotechnology has shown 40% more efficiency compared to regular tranexamic acid*.
NANOENCAPSULATED
TRANEXAMIC ACID
_edited.jpg)
_edited.jpg)
A next-generation active known for its role in supporting skin affected by visible pigmentation, inhibiting melanin synthesis. Nano-encapsulation enables targeted delivery, improving skin tolerance and ensuring controlled release.
NANOENCAPSULATED
CYSTEAMINE
%20(2).png)
%20(2).png)
Help promote gentle skin renewal and improve surface texture, supporting a smoother, more radiant appearance and optimizing the absortion of brightening actives.
AHAs
(ALPHA HYDROXY ACIDS)


A well-established brightening active that helps reduce the appearance of uneven pigmentation and supports overall skin clarity.
ALPHA-ARBUTIN


An innovative antioxidant active, helps support skin vitality and improve tolerance.
LIPOSOMAL CINNAMON EXTRACT
DEVELOPED BY DR. LIDIA POPPE
ÉGALISER is the culmination of three years of intensive research, combined with a lifetime dedicated to skin care.
It was born from my daily observations in the clinical setting, where I learned to understand the pain and needs of those living with melasma and stubborn hyperpigmentation spots, specially in skin of color.
My mission was to transform years of attentive listening and clinical evidence into a high-performance formula that respects every skin.




